EFFICACY AND SAFETY OF ANTI-IFN.-SPECIFIC MONOCLONAL ANTIBODY, PF-06823859, ON MYOSITIS: PHASE 2 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE DERMATOMYOSITIS

被引：4

作者：

Aggarwal, R. ^{[1
]}

Domyslawska, I. ^{[2
]}

Carreira, P. ^{[3
]}

Fiorentino, D. ^{[4
]}

Sluzevich, J. ^{[5
]}

Werth, V. ^{[6
,7
]}

Banerjee, A. ^{[8
]}

Chu, M. ^{[9
]}

Oemar, B. ^{[8
]}

Salganik, M. ^{[8
]}

Sloan, A. ^{[8
]}

Vincent, M. ^{[8
]}

Peeva, E. ^{[8
]}

机构：

[1] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[2] Med Univ Bialystok, NZOZ Vitamed Hosp House, Dept Gen & Expt Pathol, Bialystok, Poland

[3] Hosp Univ 12 Octubre, Rheumatol Dept, Inst Invest Hosp 12 Octubre imas 12, Madrid, Spain

[4] Stanford Univ, Dept Dermatol, Sch Med, Redwood City, CA USA

[5] Mayo Clin, Dept Dermatol, Jacksonville, FL USA

[6] Univ Penn, Philadelphia, PA USA

[7] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA

[8] Pfizer Inc, Cambridge, MA USA

[9] Pfizer Inc, Collegeville, PA USA

来源：

关键词：

Myositis; Cytokines and chemokines; Rare/orphan diseases;

D O I：

10.1136/annrheumdis-2023-eular.3230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS1207

引用

页码：936 / 937

页数：2